Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on April 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Preliminary Q1 2026 acquired IPR&D and milestone expense: $744 million pre-tax.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary Q1 2026 acquired IPR&D and milestone expense: $744 million pre-tax
- Expense expected to reduce GAAP and adjusted EPS by $0.41
- Q1 2026 adjusted EPS guidance, including expense: $2.56-$2.60
- Full-year 2026 adjusted EPS guidance, including expense: $13.96-$14.16
- Results remain subject to closing procedures and may differ from preliminary estimates
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 acquired IPR&D and milestones expense: $744 million
- Q1 adjusted diluted EPS guidance: $2.56–$2.60, reduced $0.41 by the expense
- Full-year 2026 adjusted diluted EPS guidance: $13.96–$14.16, reduced $0.41
- Guidance excludes acquired IPR&D and milestones expenses beyond Q1, limiting forecast visibility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.